Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63

Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73

Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67

Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44

100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15

Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One (2010) 1.92

Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90

Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85

Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84

Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord (2011) 1.73

The function of α-synuclein. Neuron (2013) 1.63

Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology (2011) 1.59

Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53

Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52

Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol (2012) 1.48

Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol (2008) 1.46

Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol (2008) 1.45

Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology (2015) 1.44

Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41

Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37

Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord (2011) 1.35

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31

TDP-43 immunoreactivity in neurodegenerative disorders: disease versus mechanism specificity. Acta Neuropathol (2007) 1.27

Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27

Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology (2008) 1.24

Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev (2014) 1.17

Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (2006) 1.16

Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol (2012) 1.14

Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology (2013) 1.13

Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol (2014) 1.13

Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther (2014) 1.11

Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol (2009) 1.11

Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol (2008) 1.10

Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. Neurology (2013) 1.10

An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry (2012) 1.09

Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat (2007) 1.08

Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06

Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging (2009) 1.04

Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. Neuroimage (2007) 1.04

Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism Relat Disord (2011) 1.00

Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain. Mol Psychiatry (2012) 0.95

Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease. Arch Neurol (2010) 0.95

Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95

Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J (2012) 0.93

Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm (Vienna) (2014) 0.92

MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology (2013) 0.91

Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89

The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther (2014) 0.88

Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord (2008) 0.88

Early Alzheimer's disease neuropathology detected by proton MR spectroscopy. J Neurosci (2014) 0.87

Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther (2014) 0.86

Clinical Features of Alzheimer Disease With and Without Lewy Bodies. JAMA Neurol (2015) 0.85

A novel tau mutation, p.K317N, causes globular glial tauopathy. Acta Neuropathol (2015) 0.84

Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci (2016) 0.84

Pathology and temporal onset of visual hallucinations, misperceptions and family misidentification distinguishes dementia with Lewy bodies from Alzheimer's disease. Parkinsonism Relat Disord (2012) 0.84

Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. Am J Pathol (2010) 0.83

Argyrophilic grain disease as a neurodegenerative substrate in late-onset schizophrenia and delusional disorders. Eur Arch Psychiatry Clin Neurosci (2013) 0.83

Treatment of dementia with lewy bodies. Curr Treat Options Neurol (2013) 0.81

Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. Parkinsonism Relat Disord (2014) 0.81

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology (2017) 0.81

Hippocampal Sclerosis of Aging Can Be Segmental: Two Cases and Review of the Literature. J Neuropathol Exp Neurol (2015) 0.80

Limbic lobe microvacuolation is minimal in Alzheimer's disease in the absence of concurrent Lewy body disease. Int J Clin Exp Pathol (2008) 0.80

Quantitative neuropathological assessment to investigate cerebral multi-morbidity. Alzheimers Res Ther (2014) 0.77

Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. Alzheimers Res Ther (2015) 0.76

Clinicopathological correlates of lewy body disease: fundamental issues. J Mov Disord (2010) 0.75

α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP. PLoS One (2017) 0.75

Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis (2017) 0.75

Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol (2017) 0.75

Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea. Yonsei Med J (2017) 0.75

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07

Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10

Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92

Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00

TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98

Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron (2013) 5.91

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10

Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73

Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36

Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07

Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet (2009) 4.00

DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87

Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75

Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66

Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2009) 3.65

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol (2011) 3.63

Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36

The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35

Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34

Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08

Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97

A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95

Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90

Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76

Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol (2007) 2.68

A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A (2011) 2.68

Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci (2010) 2.60

Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48

Abeta40 inhibits amyloid deposition in vivo. J Neurosci (2007) 2.47

Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain (2009) 2.45

Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43

Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation (2007) 2.43

Risk factors for dementia with Lewy bodies: a case-control study. Neurology (2013) 2.38

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30

Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29

Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet (2012) 2.23

Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol (2010) 2.20

Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20

Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19

Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol (2011) 2.17

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17

Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol (2012) 2.09

Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08

Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet (2012) 2.07

Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord (2012) 2.02

Clinically undetected motor neuron disease in pathologically proven frontotemporal lobar degeneration with motor neuron disease. Arch Neurol (2006) 2.02

Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02

Lrrk2 and Lewy body disease. Ann Neurol (2006) 2.00

Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00

Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00

Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci (2006) 1.98

Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98

Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol (2013) 1.95

Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain (2009) 1.93

Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol (2008) 1.93

Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2004) 1.92

Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging (2006) 1.92

TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol (2014) 1.90

Rates of cerebral atrophy differ in different degenerative pathologies. Brain (2007) 1.90

Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol (2009) 1.89

Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol (2005) 1.85

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener (2013) 1.83

Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol (2008) 1.81

Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord (2011) 1.73

Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol (2008) 1.72

C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology (2013) 1.70

In situ hybridization for detection of nocardial 16S rRNA: reactivity within intracellular inclusions in experimentally infected cynomolgus monkeys--and in Lewy body-containing human brain specimens. Exp Neurol (2003) 1.68

Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61

Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60

Neurofilament inclusion body disease: a new proteinopathy? Brain (2003) 1.59

Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol (2003) 1.58

SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics (2013) 1.58

Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol (2011) 1.57

Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57

Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci (2008) 1.54

DNAJC13 mutations in Parkinson disease. Hum Mol Genet (2013) 1.54

Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol (2014) 1.54

Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol (2008) 1.53

An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52

Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol (2013) 1.52

Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain (2006) 1.51

Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions. Acta Neuropathol (2008) 1.49